Ferring acquires ex-U.S. assets and rights for Vitaros® (alprostadil cream), Apricus’ on-demand topical cream for erectile dysfunction
- by pulseFerring Pharmaceuticals today announced an agreement with Apricus Biosciences, Inc. (Nasdaq:APRI), granting Ferring global…
pulseFerring Announces Recipients of Innovation Grants Program 2016-2017
- by pulseFerring today announced the recipients of the 2016-2017 Ferring Innovation Grants program, an annual initiative of the Ferring Research Institute…
pulseFerring and Foresee Pharmaceuticals Enter into Exclusive Development and Option Agreement
- by pulseFerring Pharmaceuticals and Foresee Pharmaceuticals Co., Ltd. (6576.TWO), announced today that the companies have entered into an exclusive…
pulseFerring Pharmaceuticals and Enteris BioPharma Enter License Agreement to Develop an Oral Formulation of a Peptide-based Injectable Therapeutic
- by pulseFerring Pharmaceuticals and Enteris BioPharma, Inc. announced today that the companies have entered…
pulseFerring partners with Intralytix to develop bacteriophage treatments for conditions associated with the microbiome and drug-resistant bacteria
- by pulseFerring Pharmaceuticals is partnering with Intralytix, Inc to develop and commercialise bacteriophage-based treatments…
pulse
Archives Press release 2017
Archives Press release 2017